Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Kreis, Willi
31  Ergebnisse:
Personensuche X
?
1

Synergistic and antagonistic combinations of drugs in human..:

Budman, Daniel R ; Calabro, Anthony ; Kreis, Willi
Anti-Cancer Drugs.  13 (2002)  10 - p. 1011-1016 , 2002
Link: https://doi.org/10.1097/..
 
?
2

Phase I and pharmacokinetic study of LY309887: a specific i..:

Budman, Daniel ; Johnson, Robert ; Barile, Barbara...
Cancer Chemotherapy and Pharmacology.  47 (2001)  6 - p. 525-531 , 2001
Link: https://doi.org/10.1007/..
 
?
3

A reexamination of PSC 833 (Valspodar) as a cytotoxic agent..:

Kreis, Willi ; Budman, Daniel R. ; Calabro, Anthony
Cancer Chemotherapy and Pharmacology.  47 (2000)  1 - p. 78-82 , 2000
Link: https://doi.org/10.1007/..
 
?
4

Phosphorylation/Dephosphorylation of Androgen Receptor as a..:

Wang, Long G. ; Liu, Xiao M. ; Kreis, Willi.
Biochemical and Biophysical Research Communications.  259 (1999)  1 - p. 21-28 , 1999
Link: https://doi.org/10.1006/..
 
?
5

The effect of antimicrotubule agents on signal transduction..:

Wang, Long G. ; Liu, Xiao M. ; Kreis, Willi.
Cancer Chemotherapy and Pharmacology.  44 (1999)  5 - p. 355-361 , 1999
Link: https://doi.org/10.1007/..
 
?
6

Synergistic effect of estramustine and [3′-keto-Bmtl]-[Val2..:

Wang, Long G ; Liu, Xiao M ; Budman, Daniel R.
Biochemical Pharmacology.  58 (1999)  7 - p. 1115-1121 , 1999
Link: https://doi.org/10.1016/..
 
?
7

Androgen Antagonistic Effect of Estramustine Phosphate (EMP..:

Wang, Long G ; Liu, Xiao M ; Kreis, Willi.
Biochemical Pharmacology.  55 (1998)  9 - p. 1427-1433 , 1998
Link: https://doi.org/10.1016/..
 
?
8

In vitro evaluation of synergism or antagonism with combina..:

Budman, Daniel R ; Calabro, Anthony ; Kreis, Willi
Anti-Cancer Drugs.  9 (1998)  8 - p. 697-702 , 1998
Link: https://doi.org/10.1097/..
 
?
9

Symptomatic Improvement Associated With Combined Estramusti..:

Attivissimo, Lori A. ; Fetten, James V. ; Kreis, Willi
American Journal of Clinical Oncology.  19 (1996)  6 - p. 581-583 , 1996
Link: https://doi.org/10.1097/..
 
?
10

Phase I/II dose-escalation study of liarozole in patients w..:

Seidmon, E. James ; Trump, Donald L. ; Kreis, Willi...
Annals of Surgical Oncology.  2 (1995)  6 - p. 550-556 , 1995
Link: https://doi.org/10.1007/..
 
?
11

Phase II trial and pharmacokinetic assessment of intravenou..:

Smith, David C. ; Jodrell, Duncan I. ; Egorin, Merrill J....
Cancer Chemotherapy and Pharmacology.  31 (1993)  5 - p. 363-368 , 1993
Link: https://doi.org/10.1007/..
 
?
12

Therapy of refractory/relapsed acute myeloid leukemia and b..:

Marsh, Jonathan H. ; Kreis, Willi ; Barile, Barbara...
Cancer Chemotherapy and Pharmacology.  31 (1993)  6 - p. 481-484 , 1993
Link: https://doi.org/10.1007/..
 
?
13

Pharmacokinetics of ara-C and ara-U in plasma and CSF after..:

DeAngelis, Lisa M. ; Kreis, Willi ; Chan, Keith..
Cancer Chemotherapy and Pharmacology.  29 (1992)  3 - p. 173-177 , 1992
Link: https://doi.org/10.1007/..
 
?
14

Phase I trial of intravenous vinzolidine (LY 104208) given ..:

Budman, Daniel R. ; Kreis, Willi ; Behr, Joanne...
Investigational New Drugs.  8 (1990)  3 - p. 269-274 , 1990
Link: https://doi.org/10.1007/..
 
?
15

Inhibition of HIV replication by Hyssop officinalis extract:

Kreis, Willi ; Kaplan, Mark H. ; Freeman, Jean..
Antiviral Research.  14 (1990)  6 - p. 323-337 , 1990
Link: https://doi.org/10.1016/..
 
1-15